menu search

Bellicum announces presentation by unc at ash 2022 on potential abrogation of ic9 car t-cell toxicities with rimiducid

HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunot...

December 11, 2022, 3:00 pm


Search within

Pages Search Results: